Concepedia

Hermann Wiebringhaus

HW

Statistics

Publications

6

Citations

758

H-Index

6

Active since

2015

Affiliations

Rotkreuzklinikum München(Current)

Kliniken Essen-Mitte

Charité - Universitätsmedizin Berlin

Helios Hospital Berlin-Buch

Marien Hospital Witten

Hermann Wiebringhaus is an author at Rotkreuzklinikum München specializing in pharmacology, breast oncology, and medicine.

Publications per year

2015–2019

6

Publications

6

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

Michael Untch, Christian Jackisch, Andreas Schneeweiß et al. · The Lancet Oncology · 2016 · 414 citations

, , +10

NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto

Michael Untch, Christian Jackisch, Andreas Schneeweiß et al. · Journal of Clinical Oncology · 2019 · 156 citations

, , +17

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Sibylle Loibl, Christian Jackisch, Sabine Schmatloch et al. · Annals of Oncology · 2016 · 117 citations

, , +15

Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Jenny Furlanetto, Christian Jackisch, Michael Untch et al. · Breast Cancer Research and Treatment · 2017 · 29 citations

, , +13

Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69

Michael Untch, Christian Jackisch, Andreas Schneeweiß et al. · Cancer Research · 2015 · 22 citations

, , +17

1–5 of 6